Search - tctmd.com

Displaying 981 - 1000 of 1160

Sort: Relevancy | Date

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

TAVR 可用于治疗二尖瓣主动脉瓣狭窄，但与永久性起搏器植入率更高相关联

Michael O'Riordan

July 05, 2016

News Daily News

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

Michael O'Riordan

July 05, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

La Intervención TAVR para el Manejo de la Estenosis de la Válvula Aórtica Bicúspide es Viable pero se asocia a un Índice Más Alto de Implantación de Marcapasos Permanente

Michael O'Riordan

July 05, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

Michael O'Riordan

June 29, 2016

News Daily News

FDA Warns of Class I Recall for HeartWare VAD Batteries

Michael O'Riordan

June 29, 2016

News Daily News

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Michael O'Riordan

June 28, 2016

News Daily News

Black Individuals Have Less A-fib, but When They Do, the Consequences Are More Dire

Michael O'Riordan

June 24, 2016

News Daily News

TAVR 后持续低流量主动脉瓣狭窄与较高的 1 年死亡率相关

Michael O'Riordan

June 23, 2016

News Daily News

Persistent Low-Flow Aortic Stenosis After TAVR Linked With Higher 1-Year Mortality

Michael O'Riordan

June 23, 2016

News Daily News

La Estenosis Aórtica Persistente de Bajo Flujo Post-TAVR se asocia a una Mortalidad Más Alta al cabo de 1 Año

Michael O'Riordan

June 23, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

Advertisement

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

TAVR 可用于治疗二尖瓣主动脉瓣狭窄，但与永久性起搏器植入率更高相关联

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

La Intervención TAVR para el Manejo de la Estenosis de la Válvula Aórtica Bicúspide es Viable pero se asocia a un Índice Más Alto de Implantación de Marcapasos Permanente

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

FDA Warns of Class I Recall for HeartWare VAD Batteries

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Black Individuals Have Less A-fib, but When They Do, the Consequences Are More Dire

TAVR 后持续低流量主动脉瓣狭窄与较高的 1 年死亡率相关

Persistent Low-Flow Aortic Stenosis After TAVR Linked With Higher 1-Year Mortality

La Estenosis Aórtica Persistente de Bajo Flujo Post-TAVR se asocia a una Mortalidad Más Alta al cabo de 1 Año

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content